| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T7 |
0-132 |
Sentence |
denotes |
Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. |
| T8 |
133-196 |
Sentence |
denotes |
Antiviral therapy is the most important treatment for COVID-19. |
| T9 |
197-344 |
Sentence |
denotes |
Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. |
| T10 |
345-522 |
Sentence |
denotes |
CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. |
| T11 |
523-609 |
Sentence |
denotes |
These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. |
| T12 |
610-759 |
Sentence |
denotes |
A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. |
| T13 |
760-985 |
Sentence |
denotes |
Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. |
| T14 |
986-1146 |
Sentence |
denotes |
However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. |
| T15 |
1147-1250 |
Sentence |
denotes |
Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. |
| T16 |
1251-1542 |
Sentence |
denotes |
Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies. |
